Adage Capital Partners Gp, L.L.C. Inhibrx, Inc. Transaction History

Adage Capital Partners Gp, L.L.C.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$18.45 - $27.14 $1.38 Million - $2.04 Million	-75,000 Reduced 62.74%	44,541 $840,000
Q4 2022 Feb 14, 2023	BUY	$20.18 - $33.33 $1.4 Million - $2.32 Million	69,541 Added 139.08%	119,541 $2.95 Million
Q3 2022 Nov 14, 2022	BUY	$11.58 - $24.73 $579,000 - $1.24 Million	50,000 New	50,000 $898,000
Q2 2022 Aug 15, 2022	SELL	$8.52 - $25.26 $9.84 Million - $29.2 Million	-1,154,348 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$19.89 - $43.18 $9.95 Million - $21.6 Million	500,000 Added 76.41%	1,154,348 $25.7 Million
Q4 2021 Feb 14, 2022	BUY	$26.75 - $46.02 $9.48 Million - $16.3 Million	354,348 Added 118.12%	654,348 $28.6 Million
Q3 2021 Nov 15, 2021	BUY	$25.18 - $37.81 $7.55 Million - $11.3 Million	300,000 New	300,000 $9.99 Million

18.6K

Ticker INBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,057,700
Market Cap $603M
Description
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...

Get notified when there are updates to the investment portfolio of Adage Capital Partners Gp, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Adage Capital Partners Gp, L.L.C. with notifications on news.